Sunday, February 25, 2024
HomeBiologyStructural foundation of G protein–Coupled receptor CMKLR1 activation and signaling induced by...

Structural foundation of G protein–Coupled receptor CMKLR1 activation and signaling induced by a chemerin-derived agonist


Chemerin is a 163-amino acid preprotein encoded by the retinoic acid receptor responder protein 2 (RARRES 2) gene that’s up-regulated by the retinoid drug tazarotene [14]. Cleavage of the N-terminal 20-amino acid sign peptide and the C-terminal 6-amino acid section results in probably the most energetic type of chemerin containing residues 21–157, which capabilities because the endogenous ligand to activate the chemokine-like receptor 1 (CMKLR1) or chemerin receptor 23 (ChemR23) or chemerin receptor 1 [25]. Different isoforms of chemerin because of cleavage at totally different websites of the C-terminal area have additionally been detected in vivo with decrease potencies in activating CMKLR1 in comparison with the 21–157 isoform [1]. CMKLR1 belongs to a household of Gi-coupled chemoattractant G protein–coupled receptors (GPCRs) within the γ-subgroup of the Class A GPCRs [6]. Different members of this household as shut phylogenetic neighbors of CMKLR1 embody receptors for anaphylatoxin C5a, formyl peptides, and prostaglandin D2 (PGD2) [6].

Chemerin is often thought-about as an adipocytokine or adipokine since it’s produced by adipocytes and might act on CMKLR1 to control adipogenesis and vitality metabolism in adipose tissue [1,4,7,8]. Elevated ranges of chemerin and CMKLR1 have been linked to weight problems and insulin resistance [3,4,8]. As well as, the chemerin-CMKLR1 signaling axis additionally performs pleiotropic roles in irritation. Chemerin can act as a potent chemoattractant to boost chemotaxis of monocytes particularly dendritic cells (DCs) by means of CMKLR1 signaling [4,7,9,10]. On this respect, the activation of CMKLR1 promotes the onset of irritation. Then again, quite a few research recommended that the signaling of CMKLR1 may additionally resolve irritation [1,7,9]. Such multifaceted practical roles in irritation are additionally noticed for an additional chemoattractant GPCR, the formyl peptide receptor 2 (FPR2) [11,12], which is intently associated to CMKLR1.

The obvious contradictory practical roles of CMKLR1 in irritation could also be related to the spatiotemporal regulation of the irritation processes in cells. It’s attainable that within the early stage of irritation, the CMKLR1 signaling is especially pro-inflammatory by selling chemotaxis and activation of DCs and macrophages, whereas on the late stage of irritation, CMKLR1 activation can induce pro-resolving pathways to dampen irritation. One other risk for the differing results of CMKLR1 signaling on irritation is that totally different chemerin isoforms might activate CMKLR1 to induce distinct signaling outcomes [1]. Certainly, 2 artificial peptides, chemerin9 [13,14] and chemerin15 [15] similar to the 149–157 and the 141–155 amino acid segments of chemerin, respectively, have been characterised as steady agonists of CMKLR1 that induce anti-inflammatory results [9].

Chemerin9 has been examined and proven constructive therapeutic results in a number of animal illness fashions of cardiovascular illnesses [16,17], reminiscence impairment [18], and diabetes [19]. Curiously, latest research supplied sturdy proof indicating that the activation of CMKLR1 mediates the protecting results of ω3-polyunsaturated fatty acids (PUFAs) in aortic valve stenosis 18, atherosclerosis 19, pulmonary hypertension [20], and melancholy [21,22], which contain resolvin E1 (RvE1) [23,24]. RvE1 is a specialised pro-resolvin lipid mediator (SPM) that has been recommended to behave on CMKLR1 to advertise the decision of irritation [2527]. Nevertheless, it’s not clear whether or not RvE1 can immediately bind to and activate CMKLR1 to induce Gi signaling.

The potential roles of CMKLR1 signaling in irritation might present promising new alternatives for creating anti-inflammatory medicine. Nevertheless, though there are many peptide agonists derived from chemerin, the restricted availability of artificial ligands of CMKLR1 has impeded pharmacological investigation and drug improvement on this space. One potent antagonist of CMKLR1 named CCX832 has been recognized, however the chemical construction stays undisclosed. Moreover, just a few 2-aminobenzoxazole analogues have been reported as CMKLR1 inhibitors [28,29]. However, the one commercially accessible small-molecule CMKLR1 antagonist is α-NETA, which might goal different proteins and reveals low micromolar efficiency towards CMKLR1 [30]. As to CMKLR1 agonists, a number of chemerin-derived peptide agonists have been developed [1,7,9], and one CMKLR1 antibody that capabilities as a receptor agonist was reported to advertise irritation decision in continual colitis fashions [31]. But, no small-molecule agonists of CMKLR1 have been reported thus far. In distinction, quite a few small-molecule agonists have been developed for the intently associated pro-resolving GPCR, FPR2, as novel anti-inflammatory brokers for medical investigation [12].

To deal with these questions in CMKLR1 physiology, pharmacology, and drug improvement, we primarily targeted on the peptide agonists and solved a cryo-electron microscopy (cryo-EM) construction of the CMKLR1-Gi signaling complicated with chemerin9, which, in our assays, induced a phenotype of macrophages that doesn’t fall into the oversimplified M1- nor M2-macrophages paradigm [32]. Along with molecular dynamics (MD) simulations and mutagenesis research, our construction revealed essential molecular options for the binding of chemerin9 and make clear the molecular mechanism by which chemerin9 prompts CMKLR1 to advertise Gi signaling. The structural info is anticipated to facilitate the event of artificial small molecule agonists mimicking the motion of chemerin9 for CMKLR1.


Advanced phenotypic modifications of macrophages induced by chemerin9

Regardless of the constructive therapeutic results of chemein9 in a number of illness fashions, it stays unclear whether or not chemerin9 can induce an anti-inflammatory phenotype of macrophages. To research the practical results of the chemerin9-CMKLR1 sign axis in macrophages, we handled major human macrophages with chemerin9, together with IFNg and LPS because the reference sign molecules to induce the M1-like macrophages and IL-10 because the reference sign molecule to induce the M2-like macrophages. We then checked the expression ranges of 4 cell floor proteins, HLA-DR, CD206, CD163, and CD86 (Figs 1A and S1), that are attribute markers of various phenotypes of macrophages [33,34]. HLA-DR is a category II main histocompatibility complicated cell floor molecule, a signature cell marker for antigen-presenting cells (APCs), whereas CD86 is a selective ligand for the costimulatory molecule CD28, the activation of which is indispensable for optimum T cell prime and activation; collectively, HLA-DR and CD86 are signature cell floor markers for the canonical M1-like macrophages [34]. Then again, CD206, the mannose receptor (MR), is a glycosylated floor protein belonging to the scavenger receptor household. Equally, CD163, one other member of the scavenger receptor household, is the receptor for hemoglobin-haptoglobin complicated. The up-regulation of CD206 and CD163 in macrophages has been related to the anti-inflammatory and tissue-repair phenotype [33,35].


Fig 1. Chemerin9-induced phenotypic modifications of macrophage and general construction of the CMKLR1-Gi-scFv16 complicated with chemerin9.

(a) The MFI fold-change of HLA-DR, CD86, CD206, and CD163 in major macrophages underneath varied stimulation situations, normalized to the M0 situation (medium). Two-way ANOVA with Dunnett’s a number of comparisons check, with M0 group as management reference. n = 4, every dot represents macrophages from an unbiased donor. ns, not vital, *, p < 0.05, **, p < 0.01, ****, p < 0.0001 The underlying knowledge for Fig 1A might be present in S1 Knowledge. (b) The left and proper panels present the cryo-EM density map and the general construction, respectively. CMKLR1 is coloured in blue. Chemerin9 is coloured in orange. Gαi, Gβ, and Gγ subunits are coloured in cyan, salmon, and darkish yellow, respectively. ScFv16 is coloured in gray. CMKLR1, chemokine-like receptor 1; cryo-EM, cryo-electron microscopy; MFI, imply fluorescence depth.

In our assays, IFNg plus LPS remedy led to elevated expression of HLA-DR and CD86 and lowered the expression of CD206 and CD163 in macrophages (Fig 1A), suggesting the pro-inflammatory M1-like phenotype [32]. IL-10 remedy induced the down-regulation of HLA-DR and CD86 and the up-regulation of CD206 and CD163 in major human macrophages (Fig 1A), according to an anti-inflammatory phenotype, though the modifications have been statistically insignificant. When stimulated by chemerin9, the first human macrophages confirmed considerably decreased ranges of CD206 and CD163 as executed by IFNg plus LPS, which induced irritation (Fig 1A). Nevertheless, chemerin9 didn’t induce the up-regulation of HLA-DR or CD86, which is a signature function of the pro-inflammatory macrophages. In reality, we noticed barely lowered ranges of those 2 markers upon chemerin9 stimulation in comparison with these induced by IL-10, according to an anti-inflammatory impact (Fig 1A). Taken collectively, the outcomes recommend that the chemerin9-CMKLR1 signaling axis induced a phenotype of macrophages that doesn’t merely fall into the oversimplified classification of the M1- and the M2-macrophages paradigm. How CMKLR1 regulates irritation by way of motion on macrophages wants additional investigation.

Construction dedication and general construction of the chemerin9-CMKLR1-Gi complicated

To assemble the CMKLR1 and Gi complicated, we used the wild-type (wt) human CMKLR1 and human Gi heterotrimer containing the Gαi, Gβ1, and Gγ2 subunits, equally to what we printed beforehand in figuring out the construction of Gi-coupled FPRs [36,37]. To facilitate the expression of CMKLR1 in insect cells, we fused a peptide derived from the N-terminal 28-amino acid section of human β2-adrenergic receptor to the N-terminal finish of CMKLR1. An antibody fragment, scFv16, was used to stabilize the Gi heterotrimer [38]. The construction of the CMKLR1-Gi-scFv16 complicated with chemerin9 was decided by cryo-EM to an general decision of two.94 Å (Figs 1B and S2 and Desk 1). Most areas of CMKLR1 (from P33 to S332 together with the 7 transmembrane helices (7-TMs) and the intracellular loops 2 and three (ICL2 and ICL3)) could possibly be modeled apart from part of the extracellular loop 2 (ECL2) because of weak cryo-EM density. The clear density of the peptide ligand allowed unambiguous modeling of all 9 amino acids from Tyr149 to Ser157 of chemerin9 (residues in chemerin9 are referred to by 3-letter names, and residues in CMKLR1, G protein, and different GPCRs are referred to by 1-letter names hereafter) (Fig 1B).

CMKLR1 is intently associated to the C5a receptor (C5aR) and FPRs, all of that are Gi-coupled chemoattractant GPCRs with peptide or protein endogenous ligands [6]. The energetic construction of CMKLR1 is extremely much like that of C5aR [39], FPR1, and FPR2 [36,37,40], as indicated by the root-mean-square deviation (RMSD) within the Cα atoms at 1.219 Å, 1.284 Å, and 1.048 Å, respectively (Fig 2A). The cytoplasmic areas of those 3 receptors, together with ICL1-3, might be effectively aligned (Fig 2B), indicating a extremely conserved mechanism of receptor activation and Gi-coupling. Nevertheless, the extracellular areas of those chemotactic receptors exhibit vital structural variations (Fig 2B). Accordingly, the binding pose of chemerin9 is distinct from that of the peptide agonist fMLFII in FPR1 and FPR2, in addition to that of the C-terminal area of C5a in C5aR [39,41] (Fig 2C).


Fig 2. Structural comparability of CMKLR1 with different chemotactic GPCRs and chemerin9 binding.

(a and b) Superimposition of the constructions of energetic CMKLR1, FPR1 (PDB ID 7T6T), FPR2 (PDB ID 7T6V), and C5aR (PDB ID 7Y65). (c) Binding poses of chemerin9, fMLFII, and C5a because the peptide agonists of CMKLR1, FPR1, and C5aR, respectively. (d) Chemerin9 binding pocket considered from the extracellular floor. (e) Interactions between chemerin9 and CMKLR1. The polar interactions are proven as dashed traces. CMKLR1, chemokine-like receptor 1; C5aR, C5a receptor; FPR1, formyl peptide receptor 1; FPR2, formyl peptide receptor 2; GPCR, G protein–coupled receptor.

In our construction, we additionally noticed sturdy cryo-EM densities on the floor of the 7-TMs possible for lipids (S3A Fig). To suit the densities, we modeled palmitic acid and ldl cholesterol molecules (S3A Fig). Notably, the two palmitic acid molecules are positioned in a groove above ICL2 amongst TM3, 4, and 5 (S3B Fig). This pocket shares excessive similarities with the allosteric websites in C5aR [41] and GPR40 [42] (S3B Fig). Specifically, one of many palmitic acid molecules aligns effectively with the GPR40 constructive allosteric modulator (PAM) AP8 when the constructions of the two receptors are superimposed (S3B Fig). This means the opportunity of creating PAMs for CMKLR1 that focus on this pocket, probably providing a brand new therapeutic avenue for this receptor.

An “S-shape” binding mode of chemerin9 to induce CMKLR1 activation

Chemerin9 adopts an “S-shape” binding mode to occupy a binding pocket in CMKLR1 that’s extremely open to the extracellular milieu (Fig 2C and 2D). The facet chain of the primary residue of chemerin9, Tyr149, folds again in direction of the binding pocket. Phe150 of chemerin9 kind π–π interplay with F190 from the ECL2 of CMKLR1 (Fig 2E). It’s to be famous that the density of Phe150 of chemerin9 is weak, which can recommend that the π–π interplay with F190 of CMKLR1 just isn’t sturdy sufficient to stabilize the residue in a single conformation. Following a flip brought on by Pro151, the C-terminal section of chemerin9 from Gly152 to Ser157 varieties a cyclic peptide-like conformation to insert into the 7TM bundle of CMKLR1 (Fig 2E). A polar interplay community is shaped among the many carbonyl teams of Phe156 and Gly152 of chemerin9 and CMKLR1 residues N1163.29 and R1784.64 (Ballesteros–Weinstein numbering [43]) (Fig 2E). The carboxylate group of Ser157 and the facet chain of Tyr149 kind hydrogen bonds with the facet chains of R2245.42 and E2836.58 of CMKLR1, respectively. Along with the polar interactions, Phe156 of chemerin9 additionally engages in hydrophobic and π–π interactions with surrounding CMKLR1 residues F882.53, H952.60, M1233.36, Y2766.51, and I3067.43 (Fig 2E).

Since there isn’t a construction of inactive CMKLR1 reported, we used a structural mannequin of inactive CMKLR1 predicted utilizing AlphaFold2 (AF construction) [4447] in our structural comparability evaluation (Fig 3A). In comparison with the AF construction of inactive CMKLR1, there are inward rearrangements of TM5 and TM7 and an outward displacement of TM6 on the cytoplasmic area of Gi-coupled CMKLR1 (Fig 3B), that are attribute of the energetic conformations of Class A GPCRs [4851]. Noticeably, the roughly 4.5-Å displacement of the cytoplasmic finish of TM6 is way much less distinguished in comparison with these noticed within the activation of different Gi-coupled receptors akin to μ-opioid receptor (roughly 10 Å) [38], the melatonin receptor MT1 (roughly 15 Å), adenosine A1 receptor (roughly 10.5 Å) [52], and rhodopsin (roughly 10 Å) [53]. This will recommend a comparatively smaller vitality barrier for CMKLR1 to vary from the inactive to the absolutely energetic conformation.


Fig 3. CMKLR1 activation.

(a) Superimposition of the energetic CMKLR1 construction (blue) to the Alphafold2-predicted inactive GPR84 construction (darkish gray). The intracellular and extracellular areas are proven in (b) and (c), respectively. (d) Residues concerned within the receptor activation on the core area of CMKLR1. The purple arrows point out conformational modifications from the inactive to the energetic conformation.

Alignment of the Gi-coupled energetic construction of CMKLR1 to the AF construction confirmed very delicate structural variations on the extracellular area together with residues within the ligand-binding pocket (Fig 3C). This suggests that the ligand-binding pocket of apo CMKLR1 is comparatively inflexible and effectively poised for chemerin binding. However, on the backside area of the binding pocket, Ser157 and Phe156 of chemerin9 trigger conformational modifications of N1163.29 and L1193.32 in TM3 because of direct steric results, which additional result in an outward shift and rotation of TM3 (Fig 3D). In consequence, M1233.36 shifts in direction of W2736.48, forcing it to maneuver in direction of and inducing vital displacement of F2696.44 (Fig 3D). For rhodopsin-like Class A GPCRs, W6.48 and F6.44 represent a conserved “activation swap” microdomain. Rearrangement of this microdomain hyperlinks extracellular agonist-binding to cytoplasmic conformational modifications in receptor activation [49,50,54,55]. Certainly, the motion of W2736.48 and F2696.44 in CMKLR1 breaks the continual helical construction of TM6, leading to an outward displacement of its cytoplasmic section (Fig 3D), a trademark of GPCR activation. W2736.48 can also be necessary for the right folding of the receptor. Mutations at this residue to Ala, Tyr, or Leu disrupted receptor membrane localization and brought about the lack of exercise of chemerin9 (S4A and S4B Fig). It’s to be famous that the AlphaFold-predicted inactive GPCR constructions is probably not totally exact. Our proposed CMKLR1 activation mechanism, which entails conformational modifications of Ser157 and Phe156 of chemerin9 and N1163.29 and L1193.32 of CMKLR1, solely represents a believable speculation.

Important molecular options for the motion of chemerin9 revealed by mutagenesis research

To research the essential molecular options of the chemerin9-CMKLR1-Gi complicated construction in receptor activation, we performed mutagenesis research utilizing Ca2+ flux assays. First, we examined 4 residues of CMKLR1, Y471.39, N1914.77, S2957.32, and L2987.35 by exchanging them to Ala (S4E Fig). These residues are near, however don’t immediately work together with, chemerin9 in our construction (S4D FIg). All 4 mutants CMKLR1 variants have been detected within the cell membrane (S4A Fig), and we didn’t detect vital modifications within the chemerin9 activation for these receptor variants (S4E Fig), suggesting a minor position of those residues within the motion of chemerin9. We then examined a sequence of mutations of CMKLR1 residues concerned within the interactions with chemerin9 in our construction. All mutants displayed cell floor expression aside from W2736.48 variants, Y2766.51A, H952.60A, and H952.60L. The F882.53A and Y471.39A variants are solely partially expressed within the membrane (S4A and S5 Figs).


Fig 4. Mutagenesis research targeted on the CMKLR1 interactions mediated by the C- and N-terminus of chemerin9.

(a) The construction of the chemerin9 (C9, orange) residue Tyr149 at N-terminus and the sequence of [A1]-chemerin9 ([A1]-C9) are proven within the left panel. Ca2+ sign transduction of wild-type CMKLR1 and receptor variants stimulated with chemerin9 is proven within the center panel. Double cycle mutant evaluation with [A1]-C9 is proven in the fitting panel. (b) The construction of the chemerin9 residue Ser157 on the C-terminus and the sequence of chemerin9-NH2 (C9-NH2) are proven within the left panel. Ca2+ sign transduction of wild-type CMKLR1 and receptor variants stimulated with chemerin9 is proven within the center panel. Double cycle mutant evaluation with C9-NH2 is proven in the fitting panel. All Ca2+ assay measurements have been carried out with transiently transfected HEK293 in triplicates and at the very least 3 occasions. Knowledge factors show imply ± SEM. Knowledge evaluation was carried out with GraphPad Prism 5.0. The underlying knowledge for Fig 4A and 4B might be present in S2 Knowledge.

On the extracellular area of CMKLR1, the primary N-terminal residue of chemerin9, Tyr149, possible engages in a weak π–π interplay [56] with F2947.31 of CMKLR1 (Fig 4A). Mutations of F2947.31 to Ala or His resulted in a lower within the efficiency of chemerin9, whereas the F2947.31L mutation elevated the utmost Ca2+ response. These findings recommend {that a} hydrophobic residue on the 7.31 place of CMKLR1 is essential in sustaining the facet chain of Tyr149 of chemerin9 within the applicable place for the binding of this peptide agonist. As well as, a brand new chemerin9 peptide with the Tyr149Ala mutation ([A1]-C9 peptide) (Desk 2) confirmed diminished efficiency for the wt receptor or the three CMKLR1 variants F2947.31A, F2947.31L, and F2947.31H, possible because of the elimination of the hydrophobic interplay between the agonist and the 7.31 residues of the receptors. The double-mutant cycle evaluation signifies that Tyr149 of chemerin9 just isn’t solely interacting with F2947.31 of CMKLR1 [57].

On the C-terminal finish of chemerin9, which is sure on the backside of the binding pocket, the carboxylate group of the final residue Ser157 is positioned in a extremely positively charged atmosphere surrounded by CMKLR1 residues R1784.64 and R2245.42 (Fig 4B). Mutations of both arginine to Ala or Gln resulted in undetec signaling exercise of CMKLR1 induced by chemerin9, indicating the essential position of the constructive cost atmosphere round Ser157 for ligand binding. Curiously, the mutation R1784.64Ok, however not R2245.42Ok, brought about the lack of CMKLR1 signaling induced by chemerin9, suggesting that the size of the facet chain of R1784.64, not solely its constructive cost, can also be important to ligand binding. To additional study the cost interactions between Ser157 of chemerin9 and CMKLR1 in ligand binding (Fig 4B), 2 chemerin9 derivatives have been generated: one mutating Ser157 to Ala ([A9]-C9) and the opposite altering the carboxylate group of Ser157 to carboxamide (C9-NH2) (S4C Fig and Desk 2). Whereas the carboxamide group in C9-NH2 is more likely to be positively charged, [A9]-C9 nonetheless maintains the final negatively charged carboxylate group. In comparison with [A9]-C9, C9-NH2 brought about a extra vital lower in efficiency, indicating that the unfavorable cost of the C-terminal finish of chemerin9 is essential to ligand binding (S4C Fig). Furthermore, whereas C9-NH2 confirmed no exercise on the three CMKLR1 variants, R1784.64A, R1784.64Ok, and R1784.64Q, it partially rescued the lack of exercise of chemerin9 on the CMKLR1 R2245.42A and R2245.42Q variants (Fig 4B). It’s attainable that the salt bridge between the C-terminal carboxylate of chemerin9 and R2245.42 of CMKLR1 is important for sustaining the ligand in the fitting conformation for activating the receptor. For C9-NH2, the carboxamide group on the C-terminus might kind polar interactions with different close by residues within the CMKLR1 R2245.42A and R2245.42Q variants, thereby stabilizing the carboxamide group within the appropriate place. Nevertheless, within the wt CMKLR1 or the R2245.42Ok variant, the same-charge repulsion might trigger this group of C9-NH2 to swing away from R224 (wt) or K224 (variant), ensuing within the considerably decrease exercise of C9-NH2 on each receptors.

Phe156 of chemerin9 performs a vital position within the interactions with the receptor, forming hydrophobic or π–π interactions with CMKLR1 residues F882.53, H952.60, M1233.36, Y2766.51, and I3067.43 (Figs 2E and 5). Persistently, when Phe156 was mutated to Ala in chemerin9, the ensuing peptide ([A8]-C9) (Desk 2) misplaced almost all exercise on CMKLR1 (Fig 5). We additionally examined the influence of mutations at 3 fragrant residues in CMKLR1, F882.53, H952.60, and Y2766.51, on ligand binding. Mutating F882.53 to Ala decreased the efficiency of chemerin9 by roughly 100-fold, however altering it to Leu or His led to a extra vital lower in agonist efficiency. These outcomes recommend that neither the aromaticity nor the scale of F882.53 is necessary for the motion of chemerin9. Moreover, there was a achieve of efficiency of [A8]-C9 for the F882.53A and F882.53L variants in comparison with the wt CMKLR1. Subsequently, whereas F882.53 is necessary in chemerin9 binding, the position of this residue seems to be complicated. Within the case of H952.60, mutation to Ala, Leu, or Lys diminished the efficiency of chemerin9 to totally different extents, probably by altering its interplay with Phe156 of chemerin9. For Y2766.51, trade by Ala utterly abolished the exercise of chemerin9, possible because of poor cell floor expression of the receptor variant (S5 Fig). Curiously, when mutated it to Leu, the efficiency of chemerin9 decreased by 10-fold, whereas mutation to Phe elevated the utmost exercise of chemerin9 (Fig 5), indicating the significance of the aromaticity of Y2766.51 for the exercise of chemerin9. Not one of the mutations of H952.60 or Y2766.51 rescued the exercise of [A8]-C9.


Fig 5. Mutagenesis research targeted on the CMKLR1 interactions mediated by Phe156 of chemerin9.

The construction of the C9 (orange) residue Phe156 and the sequence of [A8]-C9 peptide are proven within the left panel. Ca2+ sign transduction of wt CMKLR1 and receptor variants stimulated with C9 is proven within the center panel. Double cycle mutant evaluation with [A8]-C9 and receptor variants is proven in the fitting panel. The Ca2+ assays have been carried out with transiently transfected HEK293 have been carried out with at the very least 3 unbiased experiments in triplicates. Knowledge factors show imply ± SEM. The underlying knowledge for Fig 5 might be present in S3 Knowledge. CMKLR1, chemokine-like receptor 1; C9, chemerin9; wt, wild-type.

Conformational dynamics of the chemerin9-CMKLR1-Gi complicated

Chemerin9 is a potent peptide agonist of CMKLR1. To higher perceive the conformational dynamics of the receptor and chemerin9 in Gi coupling, we carried out 5 totally different units of MD simulations of the CMKLR1-Gi complicated or CMKLR within the absence or presence of chemerin9 (see particulars in Strategies). Every system was subjected to three runs of 100-ns MD simulations, leading to a complete of 1.5 microseconds of simulation knowledge. The CMKLR1-Gi complicated remained stably related all through all simulation runs with or with out chemerin9. Noticeably, we noticed that CMKLR1 exhibited barely extra conformational fluctuations within the absence of chemerin9, regardless of being coupled and stabilized by Gi (S6A Fig). These outcomes recommend that chemerin9 might additional stabilize the energetic conformation of CMKLR1 even within the presence of Gi.

As talked about above, in our cryo-EM construction, the carboxylate group of Ser157 is positioned in a positively charged atmosphere (Fig 4B). To research the influence of expenses of chemerin9 on ligand binding, we performed simulations of CMKLR1 sure to chemerin9 with each impartial and charged amino- and carboxyl-termini (N-ter and C-ter). Each charged and noncharged chemerin9 remained stably sure within the binding pocket all through the simulations, indicating that the binding is general stabilized by a community of interactions somewhat than particular pairs. But, to additional consider the binding vitality of chemerin9, we used the Molecular Mechanics/Generalized Born Floor Space (MM/GBSA) technique [58], as per earlier protocol [59] (Fig 6A). Our calculations confirmed that charged chemerin9 exhibited a decrease ΔHMM/GBSA of binding, indicating the next affinity for CMKLR1 in comparison with noncharged chemerin9 (Fig 6A). We attributed this enhance in binding affinity primarily to the charged carboxyl termini of chemerin9. That is according to our mutagenesis research suggesting the necessary position of cost–cost interactions between the C-terminal carboxylate group of chemerin9 and CMKLR1.


Fig 6. Binding of chemerin9 probed by MD simulations.

(a) MM/GBSA calculations (a number of runs of 100 ns every) indicated the extra favorable interactions achieved within the presence of charged amino acids on the C- and N-termini of chemerin9 (decrease panel), in comparison with these within the presence of impartial amino acids (higher panel). (b) Gi-bound receptor displays nearer affiliation with chemerin9, evidenced by the nearer distance between Phe156 (chemerin9) and W2736.48 (CMKLR1) noticed within the runs performed with (cyan histogram) and with out (orange histogram) Gi protein sure to the receptor. The underlying knowledge for Fig 6A and 6B might be present in S4 Knowledge. CMKLR1, chemokine-like receptor 1; MD, molecular dynamics; MM/GBSA, Molecular Mechanics/Generalized Born Floor Space.

Throughout our simulations of CMKLR1 alone with charged chemerin9, we noticed chemerin9 present process up and down actions inside the binding pocket. Nevertheless, within the presence of Gi, which stabilized the energetic conformation of CMKLR1, chemerin9 progressively inserted into the pocket and moved down in direction of W2736.48 (Fig 6B). This commentary means that the energetic CMKLR1 conformation favors an in depth distance between the peptide agonist and the transmission swap motif. It’s attainable that this state solely represents an area minimal vitality state, which was not captured by the cryo-EM construction. These findings supply new insights into how the coupled conformational dynamics of the receptor and the peptide agonist underlie receptor activation and signaling.

Molecular particulars of Gi-coupling to CMKLR1

The general Gi-coupling interplay profile in our construction of Gi-coupled CMKLR1 is extremely much like that of Gi-coupled FPR1 and FPR2. The C-terminal α5 of Gαi within the Gi-coupled CMKLR1 and FPR2, which is the most important interplay web site between Gi and receptors, might be effectively superimposed if the two receptors are aligned, suggesting a extremely conserved Gi-coupling mechanism (Fig 7A).


Fig 7. Gi-coupling to CMKLR1.

(a) Structural alignment of the FPR2-Gi and CMKLR1-Gi complexes. (b) Interactions between CMKLR1 (blue) and the α5 of Gαi (cyan). (b) Interactions between the ICL2 of CMKLR1 (blue) and Gαi (cyan).

Within the cytoplasmic cavity of CMKLR1, hydrophobic facet chains of residues I344, L348, L353, and F354 of Gαi on one facet of α5 kind hydrophobic interactions with CMKLR1 residues I2435.61, L2475.65, L252ICL3, P2586.33, and I2616.36 (Fig 7B). The facet chain of CMKLR1 R1373.50 within the conserved DR3.50Y/F/C motif varieties a hydrogen bond with the primary chain carbonyl of C351 of Gαi, which can also be noticed in lots of different GPCR-Gi complexes (Fig 7B). One other polar interplay is noticed between the facet chain of N347 of Gαi and the primary chain carbonyl of S1403.53 of CMKLR1 (Fig 7B). Along with these interactions inside the cytoplasmic cavity of CMKLR1, V145 in ICL2 of CMKLR1 varieties hydrophobic interactions with L194 in β2-β3 loop and F336 in α5 of Gαi, and N149 in ICL2 of CMKLR1 varieties a hydrogen bond with the primary chain carbonyl of D193 of Gαi (Fig 7C). No direct interactions are noticed between the receptor and the Gβγ subunits.

Throughout our MD simulations of the CMKLR1-Gi complicated, the Gi heterotrimer remained stably sure to the receptor, whatever the presence of chemerin9, throughout every 100-ns simulation run (S6A Fig). We be aware that such a timeframe is probably not lengthy sufficient to seize the potential conformational transitions of Gi heterodimer throughout activation and dissociation. The hydrophobic interactions recognized in our cryo-EM construction remained constant all through the simulations. Notably, we noticed a number of intermittent interfacial salt bridges between CMKLR1 and Gi (S6B Fig), akin to these between D312 of Gβ and K68 and K70 in ICL1 of CMKLR1, between D315 and E318 of Gαi and K254 in ICL3 of CMKLR1, and between D261 of Gαi and K325 in helix8 of CMKLR1 (S6B Fig). Curiously, a community of hydrogen bonds and salt bridges was shaped between D350 of Gαi and R137 and R151 of CMKLR1 (S5B Fig). This highlights the position of cost–cost interactions within the affiliation of Gi with CMKLR1.


The signaling pathway mediated by CMKLR1 has been reported to exhibit a twin position in irritation, with each pro- and anti inflammatory results as noticed in earlier research [7,9]. The practical consequence of CMKLR1 signaling might differ primarily based on the stage of irritation. Notably, latest analysis has highlighted the significance of the pro-resolving lipid ligand RvE [2125] in mediating a lot of the anti-inflammatory perform of CMKLR1 in the course of the decision part of irritation [60]. Our investigation utilizing major human macrophages revealed that chemerin9 induces a macrophage phenotype that’s distinct from the simplified M1 and M2 classification of pro- and anti inflammatory phenotypes, indicating a extra complicated position for CMKLR1 signaling in modulating macrophage perform. As well as, our construction of the CMKLR1-Gi complicated sure to chemerin9 reveals an “S-shape” binding mode of chemerin9 and the molecular determinants for its agonistic motion. Along with mutagenesis and MD simulations research, our construction gives insights into the mechanism of how chemerin9 prompts CMKLR1 to induce Gi signaling.

The event of medication concentrating on CMKLR1 has been restricted, with only some small molecule antagonists reported to this point. Nevertheless, a latest research has recognized an agonist antibody of CMKLR1 that confirmed promise in inducing continual decision of irritation in animal fashions with continual colitis [31]. This promising proof-of-concept research signifies that small molecule CMKLR1 agonists can also exhibit potential anti-inflammatory therapeutic results, which have but to be realized. FPR2, a intently associated chemoattractant GPCR, has additionally been recommended to advertise pro-resolving signaling [11,12]. In contrast to CMKLR1, quite a few small molecule agonists of FPR2 have been developed, with some at the moment underneath medical investigation [6164]. Earlier research from us have proven {that a} small molecule agonist of FPR2 shares the identical binding web site as peptide agonists within the backside area of the ligand-binding pocket [36,37]. Our construction of CMKLR1 revealed the molecular particulars of the ligand-binding pocket of CMKLR1 and significant molecular determinants for the agonistic motion of chemerin9. A earlier modelling research recommended a “U-shape” binding mode of chemerin9 primarily based on comparability of cyclic and linear chemerin9 peptide variants [65]. In our construction, chemerin9 adopts an “S-shape” binding mode because it within the lately printed construction of the CMKLR1-Gi-chemerin9 complicated [66]. In reality, the two independently decided constructions exhibit a excessive diploma of superimposition, significantly for the receptor and chemerin9, thereby offering additional validation for our construction (S7 Fig). It’s conceivable to design small molecular agonists of CMKLR1 that mimic the binding of chemerin9 in our construction as novel pro-resolving or anti-inflammatory therapeutics. As well as, our construction recommended a possible lipid-binding web site above ICL2 (S3B Fig), which may function the allosteric binding web site for RvE1. Curiously, quite a few allosteric modulators for C5aR, an in depth phylogenetic neighbor of CMKLR1, together with avacopan, a drug for treating an autoimmune illness, goal an identical web site proper above ICL2 of C5aR [41]. Subsequently, the event of small molecules as allosteric modulators of CMKLR1 concentrating on this web site can also be one other technique to modulate CMKLR1 signaling to be able to management irritation.

Supplies and strategies

Protein expression and purification

The coding sequence of wt human CMKLR1 was cloned into pFastBac vector with a sign peptide adopted by a FLAG tag and a peptide sequence similar to the N-terminal fragment of the human β2-adrenergic receptor, which is to facilitate protein expression in Sf9 cells, earlier than the N-terminal finish and a C-terminal 8xHis tag. For the Gi protein, a dominant unfavorable type of Gαi1 (DNGαi1) with 4 mutations (S47N, G203A, E245A, and A326S) was constructed to scale back the nucleotide binding. Human DNGαi1, human Gβ1 with an N-terminal His6-tag, human Gγ2, and a single-chain antibody scFv16 have been cloned into pFastBac vector.

CMKLR1, DNGαi1, and Gβ1γ2 have been coexpressed in Sf9 insect cells utilizing Bac-to-Bac technique. Sf9 cells have been contaminated with 3 kinds of viruses on the ratio of 1:1:1 for 48 hours at 27°C. After an infection, cell pellets have been harvested and saved at −80°C. Cell pellets have been thawed in lysis buffer containing 20 mM HEPES (pH 7.5), 50 mM NaCl, 10 mM MgCl2, 5 mM CaCl2, 2.5 μg/ml leupeptin, 300 μg/ml benzamidine. To facilitate complicated formation, 1 μM chemerin9, 25 mU/ml Apyrase (NEB), and 100 μM TCEP was added and incubated at room temperature for two hours. The cell membranes have been remoted by centrifugation at 25,000 × g for 40 minutes after which resuspended in solubilization buffer containing 20 mM HEPES (pH 7.5), 100 mM NaCl, 0.5% (w/v) lauryl maltose neopentylglycol (LMNG, Anatrace), 0.1% (w/v) cholesteryl hemisuccinate (CHS, Anatrace), 10% (v/v) glycerol, 10 mM MgCl2, 5 mM CaCl2, 12.5 mU/ml Apyrase, 1 μM chemerin9, 2.5 μg/ml leupeptin, 300 μg/ml benzamidine, 100 μM TECP at 4°C for two hours. The supernatant was collected by centrifugation at 25,000g for 40 minutes and incubated with nickel Sepharose resin (GE Healthcare) at 4°C in a single day. The resin was washed with a buffer A containing 20 mM HEPES (pH 7.5), 100 mM NaCl, 0.05% (w/v) LMNG, 0.01% (w/v) CHS, 20 mM imidazole, and 1 μM chemerin9, 2.5 μg/ml leupeptin, 300 μg/ml benzamidine, 100 μM TECP. The complicated was eluted with buffer A containing 400 mM imidazole. The eluate was supplemented with 2 mM CaCl2 and loaded onto anti-Flag M1 antibody resin. After wash, the complicated was eluted in buffer A containing 5 mM EDTA and 200 μg/ml FLAG peptide and concentrated utilizing an Amicon Extremely Centrifugal Filter (MWCO, 100 kDa). Lastly, a 1.3 molar extra of scFv16 was added to the elution. The pattern was then loaded onto a Superdex 200 Enhance 10/300 column (GE Healthcare) preequilibrated with buffer containing 20 mM HEPES (pH 7.5), 100 mM NaCl, 0.00075% (w/v) LMNG, 0.00025% (w/v) GDN, 0.00015% (w/v) CHS, 1 μM chemerin9, and 100 μM TECP. Peak fractions of the complicated have been collected and concentrated to five mg/ml for cryo-EM experiments.

scFv16 was expressed in Hi5 insect cells utilizing Bac-to-Bac expression system. To purify the protein, the cell supernatant was collected and purified by nickel affinity chromatography earlier than the C-terminal His8-tag was eliminated by TEV protease. The protein was additional purified by measurement exclusion chromatography utilizing a Superdex 200 Enhance 100/300 GL column (GE Healthcare). The purified scFv16 have been concentrated, flash-frozen by liquid nitrogen and saved at −80°C.

cryo-EM construction dedication

Picture stacks have been subjected to patch movement correction utilizing cryoSPARC [68]. Distinction switch perform (CTF) parameters have been calculated utilizing the patch CTF estimation device. Whole of three,900,728 particles of chemerin9-CMKLR1-Gi complicated have been autopicked after which subjected to 2D classification to discard poorly outlined particles. After ab initio reconstruction and heterogeneous refinement, 242,745 particles have been subjected to nonuniform refinement and native refinement, which generated a map with an indicated international decision of two.94 Å at a Fourier shell correlation (FSC) of 0.143. Native decision was estimated in cryoSPARC [68].

The AlphaFold-predicted construction of CMKLR1 and constructions of Gi and scFv16 obtained from the FPR1-Gi-scFv16 complicated (PDB ID 7T6T) have been used as preliminary fashions for docking into the cryo-EM map utilizing Chimera [69]. The construction of chemerin9-CMKLR1-Gi was subsequently producing utilizing iterative guide constructing and adjustment in Coot [70], adopted by real-space refinement in Phenix [71]. The ultimate mannequin have been validated by Molprobity [72]. Detailed statistics for knowledge assortment, processing, and construction refinement statistics are supplied within the Desk 1.

Peptide synthesis

Basically, all used peptides have been synthesized by an orthogonal 9-fluorenylmethoxycarbonyl/tert-butyl (Fmoc/tBu) strong part peptide synthesis (SPPS) technique. The synthesis was carried out on a Syro II peptide synthesizer (MultiSynTech, Bochum, Germany) on a scale of 15 μmol per resin. A Wang-resin, which was preloaded with serine for chemerin9 (C9) was used for computerized SPPS. The coupling was carried out twice with 8 equal of the respective, Fmoc-protected amino acid activated in situ with equimolar quantities of oxyma and DIC in DMF for half-hour. By incubation with 40% piperidine in DMF (v/v) for at the very least 3 minutes and 20% piperidine in DMF (v/v) for 10 minutes, Fmoc was deprotected. Peptides have been cleaved from the resin by incubation with 90% TFA and the next scavengers: 7% thioanisole, 3% ethanedithiol (v/v/v) for 3 hours at room temperature and precipitated in ice-cold diethyl etherate −20°C for at the very least 3 hours, washed with diethyl ether.

Peptides have been purified on a preparative RP-HPLC: phenomenex Aeris Peptide XB-C18, 250 × 21.2 mm, 100 Å pore measurement, and 5 μm particle measurement (Phenomenex, Torrence, USA). A linear gradient of eluent B (0.08% TFA in ACN (v/v)) in eluent A (0.1% TFA in H2O (v/v)) was used on the column for all RP-HPLCs. For the preparative RP-HPLC, a gradient of 20% to 50% in half-hour of eluent B in A was used. Solely peptides fractions with a purity of >95% have been mixed, and the purity was decided by RP-HPLC on a Jupiter 4 μm Proteo 90 Å C12 (Phenomenex), an Aeris 3.6 μm 100 Å XB-C18 (Phenomenex) or on a Kinetex Peptide biphenyl, 250 × 4.6 mm, 100 Å, 5 μm (Phenomenex) column (Desk 1). The identification of all peptides have been confirmed by MALDI-ToF MS on an Ultraflex II and ESI-MS (Bruker Daltonics, Billerica, USA).

Mutagenesis of CMKLR1

The receptor assemble hCMKLR1b-eYFP in pVitro2 vector was used because the wild kind and template for the mutations. The variants have been named in line with the nomenclature of Ballesteros and Weinstein [43]. The receptor constructs encode the corresponding CMKLR1 sequence with a C-terminally hooked up enhanced yellow fluorescent protein (eYFP). Single-amino acid exchanges have been generated by Q5 site-directed mutagenesis (New England Biolabs GmbH, Frankfurt am Important) utilizing the suitable primer pairs that have been designed by utilizing NEBaseChanger. Sanger sequencing confirmed the identification of the constructs carried out by Microsynth Seqlab GmbH.

Ca2+ flux assays

HEK293 cells have been transfected with the wt CMKLR1 or variant plasmid and the chimeric G protein GαΔ6qi4myr in a single day utilizing Metafectene Professional in line with the producer’s protocol. The vector for the chimeric GαΔ6qi4myr protein was kindly supplied by E. Kostenis (Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany) [73]. A black 96-well plate with μClear backside was coated with 0.001% poly-D-lysine in DPBS (v/v) for 10 minutes and dried in a single day. Transfected cells have been seeded into these coated 96-well plates (100,000 cells/wells) and incubated in a single day at customary situations (5% CO2, 95% humidity, 37°C). On the next day, the Ca2+-flux assay was carried out in assay buffer (20 mM HEPES, 2.5 mM Probenecid in HBSS (pH 7.5)). Cells have been incubated with Fluo-2-AM resolution (0.3% (v/v) and Pluronic-F127 (0.3% (v/v) in assay buffer. After 1 hour of incubation at 37°C, the dye resolution was changed by 100 μl assay buffer. The basal Ca2+ stage was recorded for 20 seconds with a Flexstation 3 (Molecular Gadgets, λex = 485 nm, λem = 525 nm). The ligand was added afterwards, and the Ca2+ response was measured for an additional 40 seconds. The ensuing most over basal worth was calculated for every effectively and normalized to the highest and backside values of the management containing the wt CMKLR1 stimulated by the respective peptide. All experiments have been carried out in triplicates, and every experiment was repeated at the very least 3 occasions. Nonlinear regression was calculated utilizing GraphPad Prism 5.

Molecular dynamics (MD) simulations

MD simulation techniques and protocol.

All MD simulation techniques have been ready utilizing CHARMM-GUI [74], primarily based on the resolved chemerin9-CMKLR1-Gi complicated. For the chemerin9 peptide (Y149FPGQFAFS157), we adopted 2 totally different conformers: (i) the N- and C-termini have been charged (charged chemerin9) as (H2+-Tyr-Phe-Professional-Gly-Gln-Phe-Ala-Phe-Ser-O); and (ii) the N-and C-termini have been impartial (impartial chemerin9), through which the terminal group have been taken as (H-Tyr-Phe-Professional-Gly-Gln-Phe-Ala-Phe-Ser-OH). 5 distinct MD simulation techniques have been constructed: (1) CMKLR1- Gi complicated sure to charged chemerin9; (2) CMKLR1-Gi complicated sure to impartial chemerin9; (3) Apo CMKLR1-Gi complicated, through which the sure peptide was eliminated; (4) Apo CMKLR1, through which each Gi protein and the sure peptide have been eliminated; and (5) CMKLR1 sure to charged chemerin9, through which the Gi protein was eliminated. For every system, the protein complicated was first oriented utilizing the PPM webserver [75] after which was embedded into membrane/lipids composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), utilizing CHARMM-GUI Membrane Builder module [76], and the resolved ldl cholesterol (CHOL) molecules have been included. Totally equilibrated transferable intermolecular potential 3P (TIP3P) waters have been added to construct a simulation field of 132 × 132 × 165 Å3 or 132 × 132 × 111 Å3 for the CMKLR1-Gi complicated or CMKLR1 protein, respectively; Na+ and Cl ions have been added to acquire a 0.15 M NaCl impartial resolution. For every system, 3 runs of 100 ns MD simulations (a complete of 1.5 microseconds) have been carried out utilizing NAMD [77], following the well-established/default protocol [78,79]. VMD [80] with in-house scripts have been used for visualization and trajectory evaluation.

MM/GBSA computational protocol and parameters.

Peptide Chemerin9 binding energies have been evaluated utilizing the MM/GBSA technique [58], adopted from earlier protocol [59]. First, we took our MD trajectories generated for the chemerin9-CMKLR1 complicated, in express solvent. Second, all solvent molecules, ions, lipids, or Gi protein if any, have been faraway from every MD snapshot, yielding trajectories for CMKLR1, chemerin9 and chemerin9-CMKLR1 complicated. Third, for every of those trajectories, the MM/GBSA free vitality was calculated utilizing GBIS module [81] carried out in NAMD. The binding free vitality change ΔHMM/GBSA was calculated following earlier protocol [59] with the default parameters set within the GBIS module [81]. Briefly, CHARMM36 power subject with CMAP corrections [82] was used to calculate MM vitality. For GBSA calculations, the dielectric fixed was set to 78.5 and ion focus to 0.3 M. The floor pressure was set to 0.00542 kcal/(mol·Å2). The switching distance (switchdist) for the LJ interactions was 15 Å; the long-range electrostatic cutoff distance (pairlistdist) was 18 Å; and the cutoff (cutoff) for the nonbonded interactions was 16 Å.

Supporting info


  1. 1.
    Kennedy AJ, Davenport AP. Worldwide Union of Fundamental and Scientific Pharmacology CIII: Chemerin Receptors CMKLR1 (Chemerin1) and GPR1 (Chemerin2) Nomenclature, Pharmacology, and Perform. Pharmacol Rev. 2018;70(1):174–196. pmid:29279348
  2. 2.
    Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007;282(38):28175–28188. pmid:17635925
  3. 3.
    Roh SG, Tune SH, Choi KC, Katoh Ok, Wittamer V, Parmentier M, et al. Chemerin—a brand new adipokine that modulates adipogenesis by way of its personal receptor. Biochem Biophys Res Commun. 2007;362(4):1013–1018. pmid:17767914
  4. 4.
    Helfer G, Wu QF. Chemerin: a multifaceted adipokine concerned in metabolic issues. J Endocrinol. 2018;238(2):R79–R94. pmid:29848608
  5. 5.
    Kennedy AJ, Davenport AP. Worldwide Union of Fundamental and Scientific Pharmacology CIII: Chemerin Receptors CMKLR1 (Chemerin(1)) and GPR1 (Chemerin(2)) Nomenclature, Pharmacology, and Perform. Pharmacol Rev. 2018;70(1):174–196. pmid:29279348
  6. 6.
    Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB. The G-protein-coupled receptors within the human genome kind 5 foremost households. Phylogenetic evaluation, paralogon teams, and fingerprints. Mol Pharmacol. 2003;63(6):1256–1272. pmid:12761335
  7. 7.
    Su X, Cheng Y, Zhang G, Wang B. Chemerin in inflammatory illnesses. Clin Chim Acta. 2021;517:41–47. pmid:33631197
  8. 8.
    Xie Y, Liu L. Position of Chemerin/ChemR23 axis as an rising therapeutic perspective on obesity-related vascular dysfunction. J Transl Med. 2022;20(1):141. pmid:35317838
  9. 9.
    Mariani F, Roncucci L. Chemerin/chemR23 axis in irritation onset and backbone. Inflamm Res. 2015;64(2):85–95. pmid:25548799
  10. 10.
    Vermi W, Riboldi E, Wittamer V, Gentili F, Luini W, Marrelli S, et al. Position of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and infected pores and skin. J Exp Med. 2005;201(4):509–515. pmid:15728234
  11. 11.
    Weiss E, Kretschmer D. Formyl-Peptide Receptors in An infection, Irritation, and Most cancers. Developments Immunol. 2018;39(10):815–829. pmid:30195466
  12. 12.
    Qin CX, Norling LV, Vecchio EA, Brennan EP, Might LT, Wootten D, et al. Formylpeptide receptor 2: Nomenclature, construction, signalling and translational views: IUPHAR evaluate 35. Br J Pharmacol. 2022;179(19):4617–4639. pmid:35797341
  13. 13.
    Shimamura Ok, Matsuda M, Miyamoto Y, Yoshimoto R, Search engine marketing T, Tokita S. Identification of a steady chemerin analog with potent exercise towards ChemR23. Peptides. 2009;30(8):1529–1538. pmid:19540290
  14. 14.
    Wittamer V, Gregoire F, Robberecht P, Vassart G, Communi D, Parmentier M. The C-terminal nonapeptide of mature chemerin prompts the chemerin receptor with low nanomolar efficiency. J Biol Chem. 2004;279(11):9956–9962. pmid:14701797
  15. 15.
    Money JL, Hart R, Russ A, Dixon JP, Colledge WH, Doran J, et al. Artificial chemerin-derived peptides suppress irritation by means of ChemR23. J Exp Med. 2008;205(4):767–775. pmid:18391062
  16. 16.
    Sato Ok, Yoshizawa H, Seki T, Shirai R, Yamashita T, Okano T, et al. Chemerin-9, a potent agonist of chemerin receptor (ChemR23), prevents atherogenesis. Clin Sci (Lond). 2019;133(16):1779–1796. pmid:31399499
  17. 17.
    Chen S, Han C, Bian S, Chen J, Feng X, Li G, et al. Chemerin-9 Attenuates Experimental Stomach Aortic Aneurysm Formation in ApoE(-/-) Mice. J Oncol. 2021;2021:6629204. pmid:33953746
  18. 18.
    Lei Z, Lu Y, Bai X, Jiang Z, Yu Q. Chemerin-9 Peptide Enhances Reminiscence and Ameliorates Abeta1-42-Induced Object Reminiscence Impairment in Mice. Biol Pharm Bull. 2020;43(2):272–283.
  19. 19.
    Tu J, Yang Y, Zhang J, Lu G, Ke L, Tong Z, et al. Regulatory impact of chemerin and therapeutic efficacy of chemerin9 in pancreatogenic diabetes mellitus. Mol Med Rep. 2020;21(3):981–988.
  20. 20.
    Liu G, Wan N, Liu Q, Chen Y, Cui H, Wang Y, et al. Resolvin E1 Attenuates Pulmonary Hypertension by Suppressing Wnt7a/beta-Catenin Signaling. Hypertension. 2021;78(6):1914–1926.
  21. 21.
    Deyama S, Shimoda Ok, Suzuki H, Ishikawa Y, Ishimura Ok, Fukuda H, et al. Resolvin E1/E2 ameliorate lipopolysaccharide-induced depression-like behaviors by way of ChemR23. Psychopharmacology. 2018;235(1):329–336. pmid:29090333
  22. 22.
    Suzuki H, Otsuka T, Hitora-Imamura N, Ishimura Ok, Fukuda H, Fujiwara Ok, et al. Resolvin E1 Attenuates Persistent Ache-Induced Melancholy-Like Habits in Mice: Attainable Involvement of Chemerin Receptor ChemR23. Biol Pharm Bull. 2021;44(10):1548–1550. pmid:34602564
  23. 23.
    Laguna-Fernandez A, Checa A, Carracedo M, Artiach G, Petri MH, Baumgartner R, et al. ERV1/ChemR23 Signaling Protects In opposition to Atherosclerosis by Modifying Oxidized Low-Density Lipoprotein Uptake and Phagocytosis in Macrophages. Circulation. 2018;138(16):1693–1705. pmid:29739755
  24. 24.
    Artiach G, Carracedo M, Plunde O, Wheelock CE, Thul S, Sjovall P, et al. Omega-3 Polyunsaturated Fatty Acids Lower Aortic Valve Illness By way of the Resolvin E1 and ChemR23 Axis. Circulation. 2020;142(8):776–789.
  25. 25.
    Arita M, Ohira T, Solar YP, Elangovan S, Chiang N, Serhan CN. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to control irritation. J Immunol. 2007;178(6):3912–3917. pmid:17339491
  26. 26.
    Ohira T, Arita M, Omori Ok, Recchiuti A, Van Dyke TE, Serhan CN. Resolvin E1 receptor activation alerts phosphorylation and phagocytosis. J Biol Chem.2010;285(5):3451–3461. pmid:19906641
  27. 27.
    Herova M, Schmid M, Gemperle C, Hersberger M. ChemR23, the receptor for chemerin and resolvin E1, is expressed and practical on M1 however not on M2 macrophages. J Immunol. 2015;194(5):2330–2337. pmid:25637017
  28. 28.
    Imaizumi T, Otsubo S, Komai M, Takada H, Maemoto M, Kobayashi A, et al. The design, synthesis and analysis of 2-aminobenzoxazole analogues as potent and orally efficacious ChemR23 inhibitors. Bioorg Med Chem. 2020;28(17):115622. pmid:32773087
  29. 29.
    Imaizumi T, Kobayashi A, Otsubo S, Komai M, Magara M, Otsubo N. The invention and optimization of a sequence of 2-aminobenzoxazole derivatives as ChemR23 inhibitors. Bioorg Med Chem. 2019;27(21):115091. pmid:31521459
  30. 30.
    Graham KL, Zhang JV, Lewen S, Burke TM, Dang T, Zoudilova M, et al. A novel CMKLR1 small molecule antagonist suppresses CNS autoimmune inflammatory illness. PLoS ONE. 2014;9(12):e112925. pmid:25437209
  31. 31.
    Trilleaud C, Gauttier V, Biteau Ok, Girault I, Belarif L, Mary C, et al. Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers continual irritation decision. Sci Adv. 2021;7(14). pmid:33811066
  32. 32.
    Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6:13. pmid:24669294
  33. 33.
    Modak M, Mattes AK, Reiss D, Skronska-Wasek W, Langlois R, Sabarth N, et al. CD206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity. JCI Perception. 2022;7 (11). pmid:35503656
  34. 34.
    Jayasingam SD, Citartan M, Thang TH, Mat Zin AA, Ang KC, Ch’ng ES. Evaluating the Polarization of Tumor-Related Macrophages Into M1 and M2 Phenotypes in Human Most cancers Tissue: Technicalities and Challenges in Routine Scientific Apply. Entrance Oncol. 2019;9:1512. pmid:32039007
  35. 35.
    Guo L, Akahori H, Harari E, Smith SL, Polavarapu R, Karmali V, et al. CD163+ macrophages promote angiogenesis and vascular permeability accompanied by irritation in atherosclerosis. J Clin Make investments. 2018;128(3):1106–1124. pmid:29457790
  36. 36.
    Zhuang Y, Liu H, Edward Zhou X, Kumar Verma R, de Waal PW, Jang W, et al. Construction of formylpeptide receptor 2-Gi complicated reveals insights into ligand recognition and signaling. Nat Commun. 2020;11(1):885. pmid:32060286
  37. 37.
    Zhuang Y, Wang L, Guo J, Solar D, Wang Y, Liu W, et al. Molecular recognition of formylpeptides and numerous agonists by the formylpeptide receptors FPR1 and FPR2. Nat Commun. 2022;13(1):1054. pmid:35217703
  38. 38.
    Koehl A, Hu H, Maeda S, Zhang Y, Qu Q, Paggi JM, et al. Construction of the micro-opioid receptor-Gi protein complicated. Nature. 2018;558(7711):547–552.
  39. 39.
    Feng Y, Zhao C, Deng Y, Wang H, Ma L, Liu S, et al. Mechanism of activation and biased signaling in complement receptor C5aR1. Cell Res. 2023;1–13.
  40. 40.
    Zhu Y, Lin X, Zong X, Han S, Wang M, Su Y, et al. Structural foundation of FPR2 in recognition of Abeta42 and neuroprotection by humanin. Nat Commun. 2022;13(1):1775.
  41. 41.
    Liu H, Kim HR, Deepak R, Wang L, Chung KY, Fan H, et al. Orthosteric and allosteric motion of the C5a receptor antagonists. Nat Struct Mol Biol. 2018;25(6):472–481. pmid:29867214
  42. 42.
    Lu J, Byrne N, Wang J, Bricogne G, Brown FK, Chobanian HR, et al. Structural foundation for the cooperative allosteric activation of the free fatty acid receptor GPR40. Nat Struct Mol Biol. 2017;24(7):570–577. pmid:28581512
  43. 43.
    Ballesteros JA, Weinstein H. Built-in strategies for the development of three-dimensional fashions and computational probing of structure-function relations in G protein-coupled receptors. Strategies Neurosci. 1995;25:366–428.
  44. 44.
    Jumper J, Evans R, Pritzel A, Inexperienced T, Figurnov M, Ronneberger O, et al. Extremely correct protein construction prediction with AlphaFold. Nature. 2021;596(7873):583–589. pmid:34265844
  45. 45.
    Tunyasuvunakool Ok, Adler J, Wu Z, Inexperienced T, Zielinski M, Zidek A, et al. Extremely correct protein construction prediction for the human proteome. Nature. 2021;596(7873):590–596. pmid:34293799
  46. 46.
    Heo L, Feig M. Multi-state modeling of G-protein coupled receptors at experimental accuracy. Proteins. 2022;90(11):1873–1885. pmid:35510704
  47. 47.
    Pandy-Szekeres G, Caroli J, Mamyrbekov A, Kermani AA, Keseru GM, Kooistra AJ, et al. GPCRdb in 2023: state-specific construction fashions utilizing AlphaFold2 and new ligand assets. Nucleic Acids Res. 2023;51(D1):D395–D402. pmid:36395823
  48. 48.
    Zhou Q, Yang D, Wu M, Guo Y, Guo W, Zhong L, et al. Widespread activation mechanism of sophistication A GPCRs. elife. 2019:8. pmid:31855179
  49. 49.
    Weis WI, Kobilka BK. The Molecular Foundation of G Protein-Coupled Receptor Activation. Annu Rev Biochem. 2018;87:897–919. pmid:29925258
  50. 50.
    Manglik A, Kruse AC. Structural Foundation for G Protein-Coupled Receptor Activation. Biochemistry. 2017;56(42):5628–5634. pmid:28967738
  51. 51.
    Glukhova A, Draper-Joyce CJ, Sunahara RK, Christopoulos A, Wootten D, Sexton PM. Guidelines of Engagement: GPCRs and G Proteins. ACS Pharmacol Transl Sci. 2018;1(2):73–83. pmid:32219204
  52. 52.
    Draper-Joyce CJ, Khoshouei M, Thal DM, Liang YL, Nguyen ATN, Furness SGB, et al. Construction of the adenosine-bound human adenosine A1 receptor-Gi complicated. Nature. 2018;558(7711):559–563. pmid:29925945
  53. 53.
    Kang Y, Kuybeda O, de Waal PW, Mukherjee S, Van Eps N, Dutka P, et al. Cryo-EM construction of human rhodopsin sure to an inhibitory G protein. Nature. 2018;558(7711):553–558. pmid:29899450
  54. 54.
    Deupi X, Standfuss J. Structural insights into agonist-induced activation of G-protein-coupled receptors. Curr Opin Struct Biol. 2011;21(4):541–551. pmid:21723721
  55. 55.
    Trzaskowski B, Latek D, Yuan S, Ghoshdastider U, Debinski A, Filipek S. Motion of molecular switches in GPCRs—theoretical and experimental research. Curr Med Chem. 2012;19(8):1090–1109. pmid:22300046
  56. 56.
    Cohen M, Reichmann D, Neuvirth H, Schreiber G. Related chemistry, however totally different bond preferences in inter versus intra-protein interactions. Proteins. 2008;72 (2):741–753. pmid:18260101
  57. 57.
    Horovitz A. Double-mutant cycles: a robust device for analyzing protein construction and performance. Fold Des. 1996;1(6):R121–R126. pmid:9080186
  58. 58.
    Genheden S, Ryde U. The MM/PBSA and MM/GBSA strategies to estimate ligand-binding affinities. Professional Opin Drug Discovery. 2015;10(5):449–461. pmid:25835573
  59. 59.
    Cheng MH, Krieger JM, Banerjee A, Xiang Y, Kaynak B, Shi Y, et al. Impression of recent variants on SARS-CoV-2 infectivity and neutralization: A molecular evaluation of the alterations within the spike-host protein interactions. iScience. 2022;25(3):103939. pmid:35194576
  60. 60.
    Serhan CN, Petasis NA. Resolvins and protectins in irritation decision. Chem Rev. 2011;111(10):5922–5943. pmid:21766791
  61. 61.
    Asahina Y, Wurtz NR, Arakawa Ok, Carson N, Fujii Ok, Fukuchi Ok, et al. Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Coronary heart Failure. J Med Chem. 2020;63(17):9003–9019. pmid:32407089
  62. 62.
    Stalder AK, Lott D, Strasser DS, Cruz HG, Krause A, Groenen PM, et al. Biomarker-guided medical improvement of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949. Br J Clin Pharmacol. 2017;83(3):476–486. pmid:27730665
  63. 63.
    Garcia RA, Lupisella JA, Ito BR, Hsu MY, Fernando G, Carson NL, et al. Selective FPR2 Agonism Promotes a Proresolution Macrophage Phenotype and Improves Cardiac Construction-Perform Submit Myocardial Infarction. JACC Fundamental Transl Sci. 2021;6(8):676–689. pmid:34466754
  64. 64.
    Maciuszek M, Cacace A, Brennan E, Godson C, Chapman TM. Latest advances within the design and improvement of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving brokers with numerous therapeutic potential. Eur J Med Chem. 2021;213:113167. pmid:33486199
  65. 65.
    Fischer TF, Schoeder CT, Zellmann T, Stichel J, Meiler J, Beck-Sickinger AG. Cyclic Analogues of the Chemerin C-Terminus Mimic a Loop Conformation Important for Activating the Chemokine-like Receptor 1. J Med Chem. 2021;64(6):3048–3058. pmid:33705662
  66. 66.
    Wang J, Chen G, Liao Q, Lyu W, Liu A, Zhu L, et al. Cryo-EM construction of the human chemerin receptor 1-Gi protein complicated sure to the C-terminal nonapeptide of chemerin. Proc Natl Acad Sci U S A. 2023;120(11):e2214324120. pmid:36881626
  67. 67.
    Mastronarde DN. Automated electron microscope tomography utilizing sturdy prediction of specimen actions. J Struct Biol. 2005;152(1):36–51. pmid:16182563
  68. 68.
    Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA. cryoSPARC: algorithms for fast unsupervised cryo-EM construction dedication. Nat Strategies. 2017;14(3):290–296. pmid:28165473
  69. 69.
    Pettersen EF, Goddard TD, Huang CC, Sofa GS, Greenblatt DM, Meng EC, et al. UCSF Chimera—a visualization system for exploratory analysis and evaluation. J Comput Chem. 2004;25(13):1605–1612. pmid:15264254
  70. 70.
    Emsley P, Lohkamp B, Scott WG, Cowtan Ok. Options and improvement of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 4):486–501. pmid:20383002
  71. 71.
    Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, et al. PHENIX: a complete Python-based system for macromolecular construction resolution. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 2):213–221. pmid:20124702
  72. 72.
    Chen VB, Arendall WB third, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, et al. MolProbity: all-atom construction validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 1):12–21. pmid:20057044
  73. 73.
    Kostenis E, Zeng FY, Wess J. Practical characterization of a sequence of mutant G protein alphaq subunits displaying promiscuous receptor coupling properties. J Biol Chem. 1998;273(28):17886–17892. pmid:9651394
  74. 74.
    Jo S, Kim T, Iyer VG, Im W. CHARMM-GUI: An online-based graphical person interface for CHARMM. J Comput Chem. 2008;29(11):1859–1865. pmid:18351591
  75. 75.
    Lomize MA, Pogozheva ID, Joo H, Mosberg HI, Lomize AL. OPM database and PPM net server: assets for positioning of proteins in membranes. Nucleic Acids Res. 2011;40(D1):D370–D376. pmid:21890895
  76. 76.
    Wu EL, Cheng X, Jo S, Rui H, Tune KC, Dávila-Contreras EM, et al. CHARMM-GUI Membrane Builder towards practical organic membrane simulations. J Comput Chem. 2014;35(27):1997–2004. pmid:25130509
  77. 77.
    Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, et al. Scalable molecular dynamics with NAMD. J Comput Chem. 2005;26(16):1781–1802. pmid:16222654
  78. 78.
    Brooks BR, Brooks CL III, Mackerell AD Jr, Nilsson L, Petrella RJ, Roux B, et al. CHARMM: The biomolecular simulation program. J Comput Chem. 2009;30(10):1545–1614. pmid:19444816
  79. 79.
    Lee J, Cheng X, Swails JM, Yeom MS, Eastman PK, Lemkul JA, et al. CHARMM-GUI Enter Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Utilizing the CHARMM36 Additive Power Subject. J Chem Concept Comput. 2016;12(1):405–413. pmid:26631602
  80. 80.
    Humphrey W, Dalke A, Schulten Ok. VMD: visible molecular dynamics. J Mol Graph. 1996;14(1):33–8, 27–8. pmid:8744570
  81. 81.
    Tanner DE, Chan Ok-Y, Phillips JC, Schulten Ok. Parallel Generalized Born Implicit Solvent Calculations with NAMD. J Chem Concept Comput. 2011;7 (11):3635–3642. pmid:22121340
  82. 82.
    Huang J, Rauscher S, Nawrocki G, Ran T, Feig M, de Groot BL, et al. CHARMM36m: an improved power subject for folded and intrinsically disordered proteins. Nat Strategies. 2017;14 (1):71–73. pmid:27819658


Please enter your comment!
Please enter your name here

Most Popular

Recent Comments